MacroGenics (Nasdaq: MGNX) has won US Food and Drug Administration approval for its HER2-targeting biologic Margenza (margetuximab-cmkb) in breast cancer.
The announcement sent shares in the East Coast, USA-based firm up nearly a fifth in pre-market trading on Thursday.
Margenza is approved, in combination with chemotherapy, for the treatment of adults with metastatic HER2-positive breast cancer, as a third-line option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze